Turkish oncologists prescribe globally recognized immune checkpoint inhibitors for lung cancer following ESMO and NCCN guidelines. These include Pembrolizumab, Nivolumab, Atezolizumab, and Durvalumab. Specialists at accredited centers determine the best drug through advanced tumor profiling and PD-L1 biomarker testing.
- PD-1 inhibitors: Doctors use Pembrolizumab and Nivolumab for advanced non-small cell lung cancer.
- PD-L1 inhibitors: Atezolizumab and Durvalumab treat both small cell and unresectable stage III cases.
- Combination therapies: Experts may combine Ipilimumab with Nivolumab for specific metastatic lung cancer types.
- Targeted sourcing: Clinics provide genuine formulations directly from global pharmaceutical manufacturers for patient safety.
Bookimed Expert Insight: Analysis shows that top Turkish oncologists, such as Dr. Yesim Yildirim and Dr. Nail Paksoy, hold ESMO board certifications. This helps patients access the same clinical protocols used in Western Europe. Many of these specialists have completed fellowships at institutions like MD Anderson or Oxford University. This international training often allows patients to join global clinical trials while receiving treatment in Istanbul or Antalya.
Patient Consensus: Patients note that doctors take the time to explain how specific biomarkers like PD-L1 affect their drug choice. They often feel more confident after receiving clear results from the hospital's advanced genetic profiling labs. Many mention they appreciate having a dedicated coordinator handle their medication schedules and hospital stays.
